Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q3 2021 · 10-Q
Revenue—
Net Income-$665.90K-$665.90KN/M vs Q3 2020 EPS Diluted-$0.02-$0.02N/M vs Q3 2020 Operating Income-$573,363N/M Operating Cash Flowderived-$539,687N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Free Cash Flowderived-$557,021— ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end